CDH1 and breast carcinoma: Recent evidence from the TCGA breast cancer study has additionally highlighted that lobular and NST carcinomas themselves harbour distinct genomic alterations aside from loss of E-cadherin, including a higher frequency of FOXA1 mutations and AKT pathway activation, suggesting different mechanisms of pathway modulation in these tumours [6].